NCCN guidelines® insights bladder cancer, version 5.2018 featured updates to the NCCN guidelines

Thomas W. Flaig; Philippe E. Spiess; Neeraj Agarwal; Rick Bangs; Stephen A. Boorjian; Mark K. Buyyounouski; Tracy M. Downs; Jason A. Efstathiou; Terence Friedlander; Richard E. Greenberg; Khurshid A. Guru; Noah Hahn; Harry W. Herr; Christopher Hoimes; Brant A. Inman; Masahito Jimbo; A. Karim Kader; Subodh M. Lele; Joshua J. Meeks; Jeff Michalski; Jeffrey S. Montgomery; Lance C. Pagliaro; Sumanta K. Pal; Anthony Patterson; Daniel P. Petrylak; Elizabeth R. Plimack; Kamal S. Pohar; Michael P. Porter; Mark A. Preston; Wade J. Sexton; Arlene O. Siefker-Radtke; Jonathan Tward; Geoffrey Wile; Alyse Johnson-Chilla; Mary A. Dwyer; Lisa A. Gurski

doi:10.6004/jnccn.2018.0072

NCCN guidelines^® insights bladder cancer, version 5.2018 featured updates to the NCCN guidelines

Thomas W. Flaig
, Philippe E. Spiess
, Neeraj Agarwal
, Rick Bangs
, Stephen A. Boorjian
, Mark K. Buyyounouski
, Tracy M. Downs
, Jason A. Efstathiou
, Terence Friedlander
, Richard E. Greenberg
, Khurshid A. Guru
, Noah Hahn
, Harry W. Herr
, Christopher Hoimes
, Brant A. Inman
, Masahito Jimbo
, A. Karim Kader
, Subodh M. Lele
, Joshua J. Meeks
, Jeff Michalski

Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Daniel P. Petrylak, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker-Radtke, Jonathan Tward, Geoffrey Wile, Alyse Johnson-Chilla, Mary A. Dwyer, Lisa A. Gurski

University of Colorado Cancer Center
University of South Florida
University of Utah
Mayo Clinic
Stanford University
University of Wisconsin-Madison
Massachusetts General Hospital Cancer Center
University of California at San Francisco
Roswell Park Comprehensive Cancer Center
Johns Hopkins University
Memorial Sloan-Kettering Cancer Center
Case Western Reserve University
Duke University
University of Michigan, Ann Arbor
University of California at San Diego
Fred and Pamela Buf-fett Cancer Center
Northwestern University
Washington University St. Louis
City of Hope National Medical Center
University of Tennessee Health Science Center
Yale University
Ohio State University
Seattle Cancer Care Alliance
Dana-Farber/Brigham and Women's Cancer Center
University of Texas MD Anderson Cancer Center
Vanderbilt University
National Comprehensive Cancer Network

Research output: Contribution to journal › Review article › peer-review

185 Scopus citations

Abstract

The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease.

Original language	English
Pages (from-to)	1041-1053
Number of pages	13
Journal	Journal of the National Comprehensive Cancer Network : JNCCN
Volume	16
Issue number	9
DOIs	https://doi.org/10.6004/jnccn.2018.0072
State	Published - Sep 1 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Administration, Intravesical
Aftercare/methods
BCG Vaccine/therapeutic use
Chemotherapy, Adjuvant/adverse effects
Cystectomy/adverse effects
Humans
Lymphatic Metastasis/diagnosis
Medical Oncology/methods
Neoadjuvant Therapy/adverse effects
Neoplasm Staging
Organ Sparing Treatments/adverse effects
Patient Selection
Quality of Life
Radiotherapy, Adjuvant/adverse effects
Randomized Controlled Trials as Topic
Societies, Medical/standards
Treatment Outcome
United States
Urinary Bladder Neoplasms/diagnosis

Access to Document

10.6004/jnccn.2018.0072

Cite this

Flaig, T. W., Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., Downs, T. M., Efstathiou, J. A., Friedlander, T., Greenberg, R. E., Guru, K. A., Hahn, N., Herr, H. W., Hoimes, C., Inman, B. A., Jimbo, M., Kader, A. K., Lele, S. M., Meeks, J. J., ... Gurski, L. A. (2018). NCCN guidelines^® insights bladder cancer, version 5.2018 featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network : JNCCN, 16(9), 1041-1053. https://doi.org/10.6004/jnccn.2018.0072

@article{5edf40128bd846a5b23214347175cb77,

title = "NCCN guidelines{\textregistered} insights bladder cancer, version 5.2018 featured updates to the NCCN guidelines",

abstract = "The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease.",

keywords = "Administration, Intravesical, Aftercare/methods, BCG Vaccine/therapeutic use, Chemotherapy, Adjuvant/adverse effects, Cystectomy/adverse effects, Humans, Lymphatic Metastasis/diagnosis, Medical Oncology/methods, Neoadjuvant Therapy/adverse effects, Neoplasm Staging, Organ Sparing Treatments/adverse effects, Patient Selection, Quality of Life, Radiotherapy, Adjuvant/adverse effects, Randomized Controlled Trials as Topic, Societies, Medical/standards, Treatment Outcome, United States, Urinary Bladder Neoplasms/diagnosis",

author = "Flaig, \{Thomas W.\} and Spiess, \{Philippe E.\} and Neeraj Agarwal and Rick Bangs and Boorjian, \{Stephen A.\} and Buyyounouski, \{Mark K.\} and Downs, \{Tracy M.\} and Efstathiou, \{Jason A.\} and Terence Friedlander and Greenberg, \{Richard E.\} and Guru, \{Khurshid A.\} and Noah Hahn and Herr, \{Harry W.\} and Christopher Hoimes and Inman, \{Brant A.\} and Masahito Jimbo and Kader, \{A. Karim\} and Lele, \{Subodh M.\} and Meeks, \{Joshua J.\} and Jeff Michalski and Montgomery, \{Jeffrey S.\} and Pagliaro, \{Lance C.\} and Pal, \{Sumanta K.\} and Anthony Patterson and Petrylak, \{Daniel P.\} and Plimack, \{Elizabeth R.\} and Pohar, \{Kamal S.\} and Porter, \{Michael P.\} and Preston, \{Mark A.\} and Sexton, \{Wade J.\} and Siefker-Radtke, \{Arlene O.\} and Jonathan Tward and Geoffrey Wile and Alyse Johnson-Chilla and Dwyer, \{Mary A.\} and Gurski, \{Lisa A.\}",

note = "Publisher Copyright: {\textcopyright} JNCCN—Journal of the National Comprehensive Cancer Network.",

year = "2018",

month = sep,

day = "1",

doi = "10.6004/jnccn.2018.0072",

language = "English",

volume = "16",

pages = "1041--1053",

journal = "Journal of the National Comprehensive Cancer Network : JNCCN",

issn = "1540-1405",

publisher = "Harborside Press",

number = "9",

}

Flaig, TW, Spiess, PE, Agarwal, N, Bangs, R, Boorjian, SA, Buyyounouski, MK, Downs, TM, Efstathiou, JA, Friedlander, T, Greenberg, RE, Guru, KA, Hahn, N, Herr, HW, Hoimes, C, Inman, BA, Jimbo, M, Kader, AK, Lele, SM, Meeks, JJ, Michalski, J, Montgomery, JS, Pagliaro, LC, Pal, SK, Patterson, A, Petrylak, DP, Plimack, ER, Pohar, KS, Porter, MP, Preston, MA, Sexton, WJ, Siefker-Radtke, AO, Tward, J, Wile, G, Johnson-Chilla, A, Dwyer, MA & Gurski, LA 2018, 'NCCN guidelines^® insights bladder cancer, version 5.2018 featured updates to the NCCN guidelines', Journal of the National Comprehensive Cancer Network : JNCCN, vol. 16, no. 9, pp. 1041-1053. https://doi.org/10.6004/jnccn.2018.0072

TY - JOUR

T1 - NCCN guidelines® insights bladder cancer, version 5.2018 featured updates to the NCCN guidelines

AU - Flaig, Thomas W.

AU - Spiess, Philippe E.

AU - Agarwal, Neeraj

AU - Bangs, Rick

AU - Boorjian, Stephen A.

AU - Buyyounouski, Mark K.

AU - Downs, Tracy M.

AU - Efstathiou, Jason A.

AU - Friedlander, Terence

AU - Greenberg, Richard E.

AU - Guru, Khurshid A.

AU - Hahn, Noah

AU - Herr, Harry W.

AU - Hoimes, Christopher

AU - Inman, Brant A.

AU - Jimbo, Masahito

AU - Kader, A. Karim

AU - Lele, Subodh M.

AU - Meeks, Joshua J.

AU - Michalski, Jeff

AU - Montgomery, Jeffrey S.

AU - Pagliaro, Lance C.

AU - Pal, Sumanta K.

AU - Patterson, Anthony

AU - Petrylak, Daniel P.

AU - Plimack, Elizabeth R.

AU - Pohar, Kamal S.

AU - Porter, Michael P.

AU - Preston, Mark A.

AU - Sexton, Wade J.

AU - Siefker-Radtke, Arlene O.

AU - Tward, Jonathan

AU - Wile, Geoffrey

AU - Johnson-Chilla, Alyse

AU - Dwyer, Mary A.

AU - Gurski, Lisa A.

N1 - Publisher Copyright: © JNCCN—Journal of the National Comprehensive Cancer Network.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease.

AB - The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease.

KW - Administration, Intravesical

KW - Aftercare/methods

KW - BCG Vaccine/therapeutic use

KW - Chemotherapy, Adjuvant/adverse effects

KW - Cystectomy/adverse effects

KW - Humans

KW - Lymphatic Metastasis/diagnosis

KW - Medical Oncology/methods

KW - Neoadjuvant Therapy/adverse effects

KW - Neoplasm Staging

KW - Organ Sparing Treatments/adverse effects

KW - Patient Selection

KW - Quality of Life

KW - Radiotherapy, Adjuvant/adverse effects

KW - Randomized Controlled Trials as Topic

KW - Societies, Medical/standards

KW - Treatment Outcome

KW - United States

KW - Urinary Bladder Neoplasms/diagnosis

UR - https://www.scopus.com/pages/publications/85053006866

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000443581300004&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.6004/jnccn.2018.0072

DO - 10.6004/jnccn.2018.0072

M3 - Review article

C2 - 30181416

SN - 1540-1405

VL - 16

SP - 1041

EP - 1053

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

IS - 9

ER -